Skip to main content
Clinical Trials/NCT06657248
NCT06657248
Not yet recruiting
Not Applicable

Prospective, Multicenter Study Evaluating the Midterm Clinical Performance and Safety of the Unicompartmental Univation® XF Pro Knee Implant

Aesculap AG8 sites in 1 country150 target enrollmentJanuary 1, 2026
Interventionsunivation® XF Pro

Overview

Phase
Not Applicable
Intervention
univation® XF Pro
Conditions
Not specified
Sponsor
Aesculap AG
Enrollment
150
Locations
8
Primary Endpoint
Functional patient-reported outcome
Status
Not yet recruiting
Last Updated
3 months ago

Overview

Brief Summary

The study is designed as a prospective, observational, mid-term, multi-center follow-up study. It is planned to include 150 patients from 4 different study centres in Germany.

Detailed Description

The product under investigation is used in routine clinical practice and according to the authorized Instructions for Use (IfU). The data that is obtained in routine clinical use will be documented in an electronical Case Report Form (eCRF). The study's main purpose is the collection of clinical data on the safety and performance of the redesigned univation® XF Pro implant.

Registry
clinicaltrials.gov
Start Date
January 1, 2026
End Date
February 1, 2031
Last Updated
3 months ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Indication for a primary medial unicompartmental knee endoprosthesis
  • Acc. to Instructions for Use:
  • Both cruciate ligaments intact
  • Lateral ligaments intact
  • Leg axis amenable to passive correction
  • Varus deformity under 15°
  • Bending capability of at least 90°
  • Extension deficit no greater than 5-10°
  • Written informed consent of patient
  • Kellgran \& Lawrence Score \> II (only straight or varus

Exclusion Criteria

  • Pregnancy
  • Patient age \<18 and \> 75 years
  • High risk patients ASA \> III

Arms & Interventions

univation® XF Pro

Primary medial unicompartmental knee arthroplasty treated with implantation of unicompartmental knee prosthesis univation® XF Pro

Intervention: univation® XF Pro

Outcomes

Primary Outcomes

Functional patient-reported outcome

Time Frame: 5 years post-op

The Oxford Knee Score (OKS) is a reliable 12-item, patient-reported questionnaire originally developed and validated specifically to assess function and pain in patients undergoing total knee replacement. It is short, reproducible, valid and sensitive to clinically important changes over time. Each of the 12 questions on the OKS is scored in the same way with the score decreasing as the reported symptoms increase (i.e. become worse). All questions are laid out with response categories denoting least (or no) symptoms to the left of the page (scoring 4) and those representing greatest severity lying on the right hand side (scoring 0), as detailed for question 1 below. This method, when summed, produces overall scores running from 0 to 48 with 48 being the best outcome.

Secondary Outcomes

  • Implant survival [Kaplan-Meier](until 5 years postoperatively)
  • Quality of Life [EQ-5D-5L] compared to baseline(Preoperatively (baseline) and 3 months, 1 year, 2 years, 5 years postoperatively)
  • Progress of Clinical Outcome [Forgotten Joint Score-12] over follow-up period(3 months, 1 year, 2 years, 5 years postoperatively)
  • Radiological assessment: axis alignment (long leg x-ray) over time(at discharge (approx. 7-10 days postoperatively), 3 months, 1 year, 2 years, 5 years postoperatively)
  • Radiological assessment: comparison of tibial slope over time(at discharge (approx. 7-10 days postoperatively), 3 months, 1 year, 2 years, 5 years postoperatively)
  • Radiological assessment: Patella x-ray(at discharge (approx. 7-10 days postoperatively), 3 months, 1 year, 2 years, 5 years postoperatively)
  • Number of Adverse events / serious adverse events over time(During the course of the study up to 5 years postoperatively)
  • Number of Participants with radiological complications over time(During the course of the study up to 5 years postoperatively)

Study Sites (8)

Loading locations...

Similar Trials